Recently, in a mouse model of ovarian cancer, the small-molecule CCR1 inhibitor UCB35625 demonstrated the ability to reduce cell migration to the greater omentum, a preferential metastatic site for such cancers (52). Here, CCR1 is linked to ovarian cancer.